Clinical Trial Finder

Inclusion Criteria:

1. Age ≥ 18 years old, ≤ 70 years old, male or female; 2. Histological or pathological diagnosis of advanced melanoma, and progressed after anti-PD-1 treatment (disease progression or unacceptable toxicity); 3. The patient has at least one (RECIST 1.1 standard) measurable lesion, which needs to be detected by spiral CT or MRI, and the tumor lesion has at least one single diameter ≥ 1 cm; 4. ECOG PS is 0 or 1 (see Annex 1 for standards); 5. The estimated survival period is ≥12 weeks; 6. no chemotherapy contraindications, including normal peripheral blood, liver and kidney function and electrocardiogram are basically normal; Peripheral blood: neutrophils ≥1.5×109/L, platelets≥90×109/ L, hemoglobin≥90 g/L; Renal function: normal serum creatinine; For patients with non-metastatic liver function impairment: alanine, aspartate aminotransferase ≤ 2.5 ULN, For patients with metastatic liver dysfunction: alanine, aspartate aminotransferase ≤ 5 ULN; 7. Patients who have undergone topical treatment for asymptomatic brain metastases can be enrolled and have a clinical stable status of at least 4 weeks. 8. Patients voluntarily participate in and sign an informed consent form. 9. contraindications for the use of no carboplatin, paclitaxel, entropic and albumin paclitaxel.

Exclusion Criteria:

1. Known HIV, hepatitis B/C virus positive status or history of active tuberculosis (testing prior to randomisation is not required) 2. Received any investigational drug within 28 days or 5 half-lives of the planned first dose of this study treatment. 3. Active infection requiring systemic therapy. 4. A known history of another malignancy or concurrent malignancy unless the patient is disease-free for a minimum of 1 year, is completely treated and is at low-risk of recurrence. 5. Patients with a history or evidence of cardiovascular risk, 6. History or evidence of interstitial lung disease or active non-infectious pneumonitis. 7. Serious or unstable pre-existing medical conditions or other conditions that could interfere with the patient's safety, consent, or compliance. 8. Pregnant or breastfeeding females, or expecting to conceive or father children within the projected period of study treatment (52 weeks followed by 4 months following end of study treatment).

The enrollment time is expected to be 1.5 year and the observation time is 2 years. The regimen were performed on a 28-day/21-day cycle respectively. Subjects who met the entry criteria were treated in a 2:1 group according to a randomized list: the treatment group was treated with nab-paclitaxel + carboplatin + endostatin regimen, and the control group was treated with paclitaxel + carboplatin. In this trial, the efficacy is evaluated every 8 weeks until disease progression or unacceptable toxicity,or until the investigator deemed that the patient's condition was unacceptable for further treatment. The follow-up period was 24 months after the end of treatment (follow-up patient survival information and new anti-tumor treatment). The planning enrolled sample size for nab-paclitaxel + carboplatin + endostatin group and paclitaxel-carboplatin group were 90 patients and 45 patients, respectively.

Arms

Experimental: nab-paclitaxel + endostatin+ carboplatin

nab-paclitaxel + endostatin+ carboplatin nab-paclitaxel 260mg/m2, d1 +Carboplatin AUC=5, d1 +endostatin 15mg, d1-14 q28d

Active Comparator: paclitaxel+carboplatin

paclitaxel+carboplatin paclitaxel 175 mg/m2, d1+ Carboplatin AUC=5, d1 q21d

Interventions

Drug: - Chemotherapeutic Combinations

nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d

Drug: - chemotherapy

paclitaxel 175 mg/m2 d1+Carboplatin AUC=5 d1, q21d